ethyl (2E)-3-(3-bromo-2-hydroxyphenyl)-2-propenoate | 1165946-48-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: ethyl (2E)-3-(3-bromo-2-hydroxyphenyl)-2-propenoate
• 英文别名: (E)-ethyl 3-(3-bromo-2-hydroxyphenyl)acrylate；ethyl (E)-3-(3-bromo-2-hydroxyphenyl)prop-2-enoate
• CAS: 1165946-48-4
• 化学式: C₁₁H₁₁BrO₃
• 分子量: 271.111
• InChiKey: YASCHXJCRNDQGK-VOTSOKGWSA-N

物化性质

• 沸点：
  343.3±32.0 °C(Predicted)
• 密度：
  1.493±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl (2E)-3-(3-bromo-2-hydroxyphenyl)-2-propenoate 在 锂硼氢 、 四(三苯基膦)钯 、 草酰氯 、 偶氮二甲酸二异丙酯 、 二甲基亚砜 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 70.5h， 生成 1,1-dimethylethyl 9-cyano-5-(2-oxoethyl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate
  参考文献：
  名称：

  Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles

  摘要：

  The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P(1) receptors, while a variety of side effects have been ascribed to its S1P(3) receptor activity. Although S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, a variety of chemotypes have been found to show S1P(1) receptor agonism. Here we describe a study of the tolerance of the S1P(1) and S1P(3) receptors toward bicyclic heterocycles of systematically varied shape and connectivity incorporating acidic, basic, or zwitterionic headgroups. We compare their physicochemical properties, their performance in in vitro and in vivo pharmacokinetic models, and their efficacy in peripheral lymphocyte lowering. The campaign resulted in the identification of several potent S1P(1) receptor agonists with good selectivity vs S1P(3) receptors, efficacy at <1 mg/kg oral doses, and developability properties suitable for progression into preclinical development.

  DOI：

  10.1021/jm5010336
• 作为产物：
  描述：

  2-溴苯酚 在 三乙胺 、 magnesium chloride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 6.83h， 生成 ethyl (2E)-3-(3-bromo-2-hydroxyphenyl)-2-propenoate
  参考文献：
  名称：

  Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles

  摘要：

  The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P(1) receptors, while a variety of side effects have been ascribed to its S1P(3) receptor activity. Although S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, a variety of chemotypes have been found to show S1P(1) receptor agonism. Here we describe a study of the tolerance of the S1P(1) and S1P(3) receptors toward bicyclic heterocycles of systematically varied shape and connectivity incorporating acidic, basic, or zwitterionic headgroups. We compare their physicochemical properties, their performance in in vitro and in vivo pharmacokinetic models, and their efficacy in peripheral lymphocyte lowering. The campaign resulted in the identification of several potent S1P(1) receptor agonists with good selectivity vs S1P(3) receptors, efficacy at <1 mg/kg oral doses, and developability properties suitable for progression into preclinical development.

  DOI：

  10.1021/jm5010336

文献信息

• Late‐Stage Direct <i>o</i> ‐Alkenylation of Phenols by Pd ^II ‐Catalyzed C−H Functionalization
  作者：Yandong Dou、Kenry、Jiang Liu、Jianze Jiang、Qing Zhu

  DOI：10.1002/chem.201900530

  日期：2019.5.17

  phenol as a directing group, high regioselectivity, good substrate scope, mild reaction conditions, and high efficiency. To the best of our knowledge, this is the first example of a regioselective C−H alkenylation of unprotected phenols utilizing phenolic hydroxyl group as a directing group. The alkenylation of unprotected tyrosine and intramolecular cyclization are also successfully carried out under

  通过Pd II催化的直接C-H官能化已开发出未保护的酚的o-烯基化。这项工作以酚基团为导向基团，并实现了酚的位点选择性C-H键官能化，从而在60°C时以中等至极好的收率获得了相应的产品。该反应的优点包括使用苯酚作为指导基团进行前所未有的CH官能化，区域选择性高，底物范围广，反应条件温和且效率高。据我们所知，这是利用酚羟基作为指导基团对未保护的酚进行区域选择性CH烯基化的第一个例子。未保护的酪氨酸的烯基化和分子内环化也可以在该催化体系下以高收率成功进行。此外，
• Visible-Light-Induced C(sp²)–C(sp³) Coupling Reaction for the Regioselective Synthesis of 3-Functionalized Coumarins
  作者：Ke Zhang、Li Qiao、Jianwei Xie、Zhenwei Lin、Hanjie Li、Ping Lu、Yanguang Wang

  DOI：10.1021/acs.joc.1c00848

  日期：2021.7.16

  A photocatalysis strategy for the regioselective synthesis of 3-functionalized coumarins is reported. With visible light irradiation, a direct and regioselective C(sp2)–C(sp3) coupling reaction of 3-(2-hydroxyphenyl)acrylates with ethers or thioethers occurs by using Ru(bpy)3Cl2·6H2O as a photocatalyst and TBHP as an oxidant. The cascade process involves alkenylation of the C(sp3)–H bond of ethers

  报道了一种用于区域选择性合成 3 官能化香豆素的光催化策略。在可见光照射下，3-(2-羟基苯基)丙烯酸酯与醚或硫醚发生直接和区域选择性的C(sp 2 )–C(sp 3 )偶联反应，使用Ru(bpy) 3 Cl 2 ·6H 2 O作为光催化剂和TBHP作为氧化剂。级联过程涉及 C(sp 3)-H 键的醚和内酯化，提供 3-烷基化香豆素作为最终产品。该方法的特点是底物范围广、反应条件温和、操作简单。3-烷基化香豆素的合成可以通过一锅法实现，从市售的水杨醛开始。
• [EN] 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES<br/>[FR] COMPOSÉS DE 1,2,4-OXADIAZOLE POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES
  申请人：GLAXO GROUP LTD

  公开号：WO2009080730A1

  公开（公告）日：2009-07-02

  The present invention relates to novel oxadiazole derivatives of formula (I) or a pharmaceutically acceptable salt thereof thereof. Compounds of formula (I) and their pharmaceutically acceptable salts are of use in the treatment of conditions or disorders which are mediated via the S1 P1 receptor. In particular the compounds of formula (I) and their pharmaceutically acceptable salts are of use in the treatment of multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependant diabetes.

  本发明涉及公式(I)的新型噁二唑衍生物或其药学上可接受的盐。公式(I)化合物及其药学上可接受的盐可用于治疗通过S1 P1受体介导的疾病或紊乱。特别是公式(I)化合物及其药学上可接受的盐可用于治疗多发性硬化症、自身免疫疾病、慢性炎症性疾病、哮喘、炎性神经病、关节炎、移植、克罗恩病、溃疡性结肠炎、红斑狼疮、银屑病、缺血再灌注损伤、实体肿瘤、肿瘤转移、与血管生成相关的疾病、血管疾病、疼痛症状、急性病毒性疾病、炎症性肠病、胰岛素依赖和非依赖性糖尿病。
• Antibacterial Agents
  申请人：Miller William Henry

  公开号：US20090054418A1

  公开（公告）日：2009-02-26

  2H-chromen-2-one derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

  本文揭示了用于治疗哺乳动物，尤其是人类细菌感染的2H-香豆素衍生物。
• 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
  申请人：Heer Jag Paul

  公开号：US20100273770A1

  公开（公告）日：2010-10-28

  The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

  本发明涉及具有药理活性的新型噁唑二氮杂环衍生物，其制备过程，包含它们的制药组合物以及它们在治疗各种疾病中的应用。